Exhaled VOCs: Can Your Breath Tell Allergic Rhinitis Apart?

Chronic rhinitis looks the same from the outside, but the causes differ:

Allergic rhinitis (AR): skin and blood allergy tests positive

Local allergic rhinitis (LAR): allergy only in the nose, skin and blood tests negative, nasal challenge positive

Non-allergic rhinitis (NAR): no allergic mechanism

LAR is especially easy to miss, affecting an estimated 16% to 25% of non-atopic rhinitis patients. The gold standard, nasal allergen challenge (NAC), is accurate but slow, uncomfortable, and not widely available.

A new study in Allergy asks whether exhaled breath could help triage who is truly allergic.

The study

Sola-Martinez and colleagues recruited 102 adults with perennial rhinitis: 28 AR, 31 LAR, 29 NAR, and 14 healthy controls. Everyone had skin testing, blood specific IgE, and NAC. Breath was collected before and 24 hours after a single-allergen nasal challenge and analyzed by thermal desorption gas chromatography-mass spectrometry.

Two molecules stood out

A model using just two exhaled VOCs, decane and nonadecane, separated allergic (AR + LAR) from non-allergic (NAR + healthy controls) people:

Validation AUC: 0.760, with 76.5% sensitivity and 69.2% specificity

The same two compounds also separated the hardest pair:

LAR vs. NAR AUC: 0.737

At baseline, both compounds were highest in LAR. Decane was higher in LAR than healthy controls (p = 0.007), and nonadecane was higher in LAR than NAR (p = 0.026).

That is not good enough to replace NAC, but it is promising as a triage test, especially for LAR patients who are missed by standard testing.

Links to inflammation

People with FeNO ≥25 ppb had higher levels of all five VOCs studied. The difference was significant for decane, styrene, and nonanal.

Adding VOCs also improved a model based on FeNO + blood eosinophils, from AUC 0.565 to 0.787 in validation. In other words, breath VOCs added information that standard type 2 markers did not already capture.

The most intriguing twist

Twenty-four hours after nasal challenge, nonadecane fell significantly in allergic patients only (p = 0.012), with no change in non-allergic people. The other VOCs and FeNO stayed stable.

That suggests nonadecane is not just a static trait marker. It responds to allergic inflammation, though the mechanism is not yet proven and only one post-challenge timepoint was tested.

The authors are clear: VOCs should not be used as a standalone diagnostic tool. A breath test cannot identify the culprit allergen, which is essential for allergen immunotherapy.

References

Sola-Martinez RA, et al. Exhaled Volatile Organic Compounds Identify Allergic Patients Among Individuals With Chronic Rhinitis. Allergy. 2026; pp. 3895-3906. DOI: 10.1111/all.70273. Primary study discussed in this post. 102 participants: 28 AR, 31 LAR, 29 NAR, 14 healthy controls. Model I based on decane + nonadecane: training AUC 0.721, validation AUC 0.760 (76.5% sensitivity, 69.2% specificity); LAR vs NAR AUC 0.737.

Medscape News Summary. Exhaled Compounds May Identify Allergic Rhinitis. Published March 9, 2026. Summary of the Sola-Martinez et al. study, including validation AUC, sensitivity/specificity, and authors’ caution that VOCs should not be used as a standalone diagnostic tool.